MetaVia Inc., a clinical-stage biotech company focused on cardiometabolic diseases, recently presented updates on its pipeline of next-generation therapeutics targeting obesity and MASH. The company's investigational drug, DA-1726, a novel GLP1R/GCGR dual agonist, is currently in Phase 1 trials and has shown promising results with significant weight loss and reductions in fasted glucose levels. Additionally, DA-1241, targeting MASH, has met its Phase 2a primary endpoint, demonstrating direct hepatic effects and a strong safety profile. MetaVia continues to explore further studies and regulatory interactions for these treatments. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。